Clinical trial · Observational
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Molecular relapse
- description
- Confirmed molecular relapse, without overt cytological relapse
- interventionNames
- Other: No intervention
- label
- Cytological relapse
- description
- Overt cytological relapse, without prior molecular relapse
- interventionNames
- Other: No intervention
- label
- Persistent responders
- description
- No molecular or cytological relapse during follow-up
- interventionNames
- Other: No intervention
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 61 Years
Show eligibility criteria text
Inclusion Criteria: * Patients between 18 and 61 years * Diagnosis between 2010 and 2019 * Core binding factor and/or NPM1 acute myeloid leukemia * First complete remission after induction therapy * Measurable residual disease measurement after end of consolidation therapy Exclusion Criteria: * Acute promyelocytic leukemia * Allogeneic stem cell transplantation in CR1
References
Publications (0)
Data not yet available